Communicators

are winners!

More News

20.09.2025
Terry Lynch Continues as Capital Markets Advisor and BioNxt Retains Investor Relations Professionals
15.09.2025
BioNxt Advances Semaglutide Oral Dissolvable Film (ODF) Program with Successful Proof-of-Concept and Prototype Development
05.09.2025
BioNxt Solutions Completes Up-Listing to The OTCQB Market
02.09.2025
Semaglutide API Delivery Enables Start of Lab-Scale ODF Development at BioNxt
20.08.2025
BioNxt Fast-Tracks U.S. Patent for MS Drug and Secures Broad Platform IP Covering Autoimmune Neurology Pipeline
05.08.2025
BioNxt Solutions Reports Pending Patent Grants in Europe and Eurasia, Strengthening IP Protection for Proprietary Sublingual Cladribine-Based MS Treatment
23.07.2025
BioNxt Delivers Positive Results in Patented Cladribine Sublingual Thin-Film Program and Completes Successful Formulation
09.07.2025
BioNxt Solutions Introduces Targeted Chemotherapy Drug Delivery Platform for Precision Oncology
07.07.2025
BioNxt’s Sublingual Cladribine Program for MS Ready for Next Phase
23.06.2025
BioNxt Launches Feasibility Study for Semaglutide Oral Thin Film as Alternative to Injection/Tablets